Buying a Toxicology Lab: Compliance Risks Lenders Review
Buying a toxicology lab can look attractive on paper. Many toxicology labs serve pain management, behavioral health and addiction treatment providers, and some report strong revenue from drug testing. But toxicology has also been one of the most heavily scrutinized segments of the laboratory industry, and lenders review these acquisitions with particular care.
This article explains the compliance risks lenders and buyers typically examine and why diligence matters even more than usual. It is a general overview from a financing perspective. Billing, coverage and enforcement rules vary, and nothing here is legal, billing, regulatory or compliance advice. Buyers should rely on experienced healthcare counsel and qualified billing and compliance professionals.
Why Toxicology Labs Draw Scrutiny
Toxicology testing has faced attention from government investigators and commercial payers for years. Concerns have included tests that were not medically necessary, broad standing orders, excessive definitive testing, billing for tests performed with screening methods, and financial relationships with referral sources.
For a buyer, the issue is not just whether the lab is profitable today. It is whether that revenue was earned in a way that can withstand payer audits and government review, and whether any past issues could follow the lab after closing.
What Lenders Review When Buying a Toxicology Lab
Lenders financing a toxicology acquisition generally go well beyond the financial statements. Areas of focus may include:
- Revenue concentration: how much volume comes from a few ordering providers or treatment facilities
- Test mix: the balance between presumptive screening and definitive testing, and how it compares with clinical need
- Ordering practices: whether orders are individualized or rely on standing orders and custom panels
- Medical necessity documentation: how the lab obtains and retains supporting documentation
- Payer mix: reliance on Medicare, Medicaid, commercial insurers or out-of-network billing
- Audit history: payer reviews, recoupments, prepayment reviews or repayment agreements
- Government inquiries: any subpoenas, investigations or settlements
A lab with heavy out-of-network billing or a small number of large referral sources may face particular skepticism.
Referral Relationships and Sales Practices
How a toxicology lab obtains its business can be as important as how it bills. Buyers and lenders often review:
- Agreements with referring providers, treatment centers and clinics
- How sales representatives and marketers are compensated
- Whether the lab provides supplies, staff, space or services to clients
- Any ownership interests held by referral sources
These arrangements raise complex legal questions and must be reviewed by healthcare counsel. Lenders may decline to finance a lab where referral arrangements are unclear or where compliance cannot be documented.
Deal Structure and Successor Liability
Structure matters in any lab acquisition, but especially in toxicology. In an equity purchase, the buyer may inherit the entity’s history, including potential overpayment liabilities. An asset purchase may limit some exposure, but certificates, licenses, payer contracts and enrollments should not be assumed to transfer, and new enrollments can delay revenue.
Our article on CLIA change of ownership explains how structure affects certification and enrollment. Purchase agreements in these deals may include escrows, holdbacks, indemnities and representations about compliance. Counsel should guide those terms.
Valuation Under Compliance Risk
Toxicology lab earnings are often discounted for risk. A buyer and lender may adjust historical earnings to exclude revenue that is unlikely to continue, such as revenue from a referral source that may not stay, payers that have begun denying claims or test practices that may need to change.
That adjustment can significantly change what the lab is worth and how much can be financed. Our guide to clinical laboratory valuation explains how compliance history and concentration affect value.
Financing a Toxicology Lab Acquisition
Financing options may include SBA-backed loans, where the business and buyer are eligible under program rules and lender review, conventional acquisition loans and, in some cases, seller financing. Lenders and programs may limit seller notes and earnouts, and seller notes are typically subordinate to the senior loan.
Lenders will generally require a buyer with relevant laboratory experience, a qualified director, a strong compliance plan and enough equity and working capital to absorb potential disruption. Some lenders may decline toxicology acquisitions altogether, while others may finance them with additional conditions. Every loan is subject to lender review and approval.
Due Diligence Checklist When Buying a Toxicology Lab
- Financial statements, tax returns and bank statements
- Revenue by ordering provider, payer and test code
- Denial, appeal and recoupment history
- Sample review of orders and medical necessity documentation, conducted by qualified professionals
- All client, marketing and sales compensation agreements
- Compliance program documents, training records and hotline logs
- Certification, licensure, proficiency testing and inspection history
- Any correspondence with payers or government agencies
Building a Post-Closing Compliance Plan
Lenders tend to look more favorably on buyers who present a clear plan for compliance after closing: updated ordering processes, client education, billing reviews, a compliance officer and periodic outside audits. A plan that assumes revenue may decline as practices are corrected can be more credible than one that assumes nothing will change. Buyers should also budget for the cost of these improvements, including staff, outside reviewers and system changes.
For a broader overview of lab acquisitions, see our guide on how to buy a clinical laboratory.
Final Thoughts
Buying a toxicology lab can be viable, but only with thorough diligence into ordering practices, billing, referral relationships and audit history. Buyers who understand those risks, structure the deal carefully and plan for compliance after closing will be better prepared for lender review.
US Medical Funding helps experienced buyers finance laboratory acquisitions. Learn more about our lab and pathology acquisition financing and our full range of laboratory and pathology financing options.
